← Back to all media
Access to fast-growing biotechnology companies
IBT was established in 1994 to provide institutional and retail investors with the opportunity to participate in global biotechnology and life science companies, from venture-stage (via a venture capital fund run by SV Health Investors) through to global, multinational biotechnology companies. The main aim of the trust is to generate capital growth, while minimising risk, through a diversified portfolio and with an experienced investment management team. Over the last five years, IBT’s NAV per share has increased 64%, while the share price has increased 79% over the same period – the superior returns generally reflected by a share price premium.
Published on 3rd December 2021